{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:41:21Z","timestamp":1780472481828,"version":"3.54.1"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00210-025-04525-w","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T10:00:10Z","timestamp":1755943210000},"page":"1689-1710","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mirtazapine revisited: new therapeutic perspectives and formulation advances"],"prefix":"10.1007","volume":"399","author":[{"given":"Anshula","family":"Mehra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vridhi","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaanvi","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurpreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manikay","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maninderdeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6403-6289","authenticated-orcid":false,"given":"Neena","family":"Bedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"4525_CR1","unstructured":"US20020072602A1, https:\/\/patents.google.com\/patent\/US20020072602A1\/en. Accessed on 16th July, 2025"},{"key":"4525_CR2","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1177\/1098612X14545273","volume":"16","author":"W Agnew","year":"2014","unstructured":"Agnew W, Korman R (2014) Pharmacological appetite stimulation: rational choices in the inappetent cat. J Feline Med Surg 16:749\u2013756. https:\/\/doi.org\/10.1177\/1098612X14545273","journal-title":"J Feline Med Surg"},{"key":"4525_CR3","doi-asserted-by":"publisher","first-page":"638651","DOI":"10.3389\/fpsyt.2021.638651","volume":"12","author":"L Ag\u00fcera-Ortiz","year":"2021","unstructured":"Ag\u00fcera-Ortiz L, Garc\u00eda-Ramos R, Grandas P\u00e9rez FJ, L\u00f3pez-\u00c1lvarez J, Montes Rodr\u00edguez JM, Olazar\u00e1n Rodr\u00edguez FJ, Olivera Pueyo J, Pelegrin Valero C, Porta-Etessam J (2021) Depression in Alzheimer\u2019s disease: a Delphi consensus on etiology, risk factors, and clinical management. Front Psychiatry 12:638651. https:\/\/doi.org\/10.3389\/fpsyt.2021.638651","journal-title":"Front Psychiatry"},{"key":"4525_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0301179J","volume":"19","author":"SR Ahmad","year":"2024","unstructured":"Ahmad SR, Zeyaullah M, AlShahrani AM, Khan MS, Muzammil K, Ahmed F, Dawria A, Mohieldin A, Ali H, Altijani AA (2024) Exploring the most promising anti-Depressant drug targeting Microtubule Affinity Receptor Kinase 4 involved in Alzheimer\u2019s Disease through molecular docking and molecular dynamics simulation. PLoS ONE 19:1\u201333. https:\/\/doi.org\/10.1371\/journal.pone.0301179J","journal-title":"PLoS ONE"},{"key":"4525_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5152\/npa.2015.8791","volume":"53","author":"\u0130N Ahmet","year":"2016","unstructured":"Ahmet \u0130N, B\u00fcy\u00fck\u015fekerci M, Ulusoy HB (2016) Antinociceptive effect of mirtazapine in rats with diabetic neuropathy. Noro Psikiyatr Ars 53:12. https:\/\/doi.org\/10.5152\/npa.2015.8791","journal-title":"Noro Psikiyatr Ars"},{"key":"4525_CR6","doi-asserted-by":"publisher","unstructured":"Aitken RJ, Roman SD (2008) Antioxidant systems and oxidative stress in the testes. In: Cheng CY, editors. Molecular Mechanisms in Spermatogenesis. Advances in Experimental Medicine and Biology. Springer, New York, pp. 154\u2013171. https:\/\/doi.org\/10.1007\/978-0-387-09597-4_9","DOI":"10.1007\/978-0-387-09597-4_9"},{"key":"4525_CR7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1272\/jnms.JNMS.2018_85-53","volume":"85","author":"F Akama","year":"2018","unstructured":"Akama F, Mikami K, Watanabe N, Kimoto K, Yamamoto K, Matsumoto H (2018) Efficacy of mirtazapine on irritable bowel syndrome with anxiety and depression: a case study. J Nippon Med Sch 85:330\u2013333. https:\/\/doi.org\/10.1272\/jnms.JNMS.2018_85-53","journal-title":"J Nippon Med Sch"},{"key":"4525_CR8","doi-asserted-by":"publisher","unstructured":"Akhtar M, Javed A, Tariq A, Mirza R, Abdur Rahman A, Khan H, Khan A (2025) Mirtazapine Loaded NLCs-Based Hydrogel for Topical Delivery in Pruritus: Statistical Optimization, In vitro and Skin Irritation Evaluation. Drug Dev Ind Pharm 51:634\u2013646.https:\/\/doi.org\/10.1080\/03639045.2025.2495846","DOI":"10.1080\/03639045.2025.2495846"},{"key":"4525_CR9","doi-asserted-by":"publisher","first-page":"27255","DOI":"10.4088\/PCC.13r01525","volume":"15","author":"A Alam","year":"2013","unstructured":"Alam A, Voronovich Z, Carley JA (2013) A review of therapeutic uses of mirtazapine in psychiatric and medical conditions. Prim Care Companion CNS Disord 15:27255. https:\/\/doi.org\/10.4088\/PCC.13r01525","journal-title":"Prim Care Companion CNS Disord"},{"key":"4525_CR10","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1007\/s13346-023-01316-9","volume":"13","author":"RA Aldeeb","year":"2023","unstructured":"Aldeeb RA, Mahdy MA, El-Nahas HM, Musallam AA (2023) Design of mirtazapine solid dispersion with different carriers\u2019 systems: optimization, in vitro evaluation, and bioavailability assessment. Drug Deliv Transl Res 13:2340\u20132352. https:\/\/doi.org\/10.1007\/s13346-023-01316-9","journal-title":"Drug Deliv Transl Res"},{"key":"4525_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.biopsych.2006.09.023","volume":"62","author":"K Alper","year":"2007","unstructured":"Alper K, Schwartz KA, Kolts RL, Khan A (2007) Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 62:345\u2013354. https:\/\/doi.org\/10.1016\/j.biopsych.2006.09.023","journal-title":"Biol Psychiatry"},{"key":"4525_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.52142\/omujecm.38.2.4","volume":"38","author":"AD An\u011f\u0131n","year":"2021","unstructured":"An\u011f\u0131n AD, Oru\u00e7 MA, Sakin \u00d6, Akal\u0131n EE, \u00c7\u0131kman M, Ba\u015fak K, Alan Y, Or\u00e7un A, Alan M (2021) Evaluation of protective effects of mirtazapine and mesna on cisplatin-induced ovarian damage in rats. J Exp Clin Med 38:72\u201381. https:\/\/doi.org\/10.52142\/omujecm.38.2.4","journal-title":"J Exp Clin Med"},{"key":"4525_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","volume":"7","author":"SA Anttila","year":"2001","unstructured":"Anttila SA, Leinonen EV (2001) A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 7:249\u2013264. https:\/\/doi.org\/10.1111\/j.1527-3458.2001.tb00198.x","journal-title":"CNS Drug Rev"},{"key":"4525_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4306\/pi.2011.8.1.55","volume":"8","author":"M Atmaca","year":"2010","unstructured":"Atmaca M, Korkmaz S, Topuz M, Mermi O (2010) Mirtazapine augmentation for selective serotonin reuptake inhibitor-induced sexual dysfunction: a retropective investigation. Psychiatry Investig 8:55. https:\/\/doi.org\/10.4306\/pi.2011.8.1.55","journal-title":"Psychiatry Investig"},{"key":"4525_CR15","doi-asserted-by":"publisher","unstructured":"Aziz HA, Abdulrahman Al-Majed*, Ahmed H. Bakheit*\u2020, Raed M. Alharbi. (2018) Mirtazapine. In: Brittain HG, editor. Profiles of Drug Substances, Excipients, and Related Methodology. Elsevier, United States, pp. 209\u2013254. https:\/\/doi.org\/10.1016\/bs.podrm.2018.01.002","DOI":"10.1016\/bs.podrm.2018.01.002"},{"key":"4525_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0140-6736(11)60830-1","volume":"378","author":"S Banerjee","year":"2011","unstructured":"Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Knapp M (2011) Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 378:403\u2013411. https:\/\/doi.org\/10.1016\/S0140-6736(11)60830-1","journal-title":"Lancet"},{"key":"4525_CR17","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/S0140-6736(21)01210-1","volume":"398","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, High J, Stirling S, Shepstone L, Swart AM, Telling T, Henderson C, Ballard C, Bentham P, Burns A, Farina N (2021) Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. Lancet 398:1487\u20131497. https:\/\/doi.org\/10.1016\/S0140-6736(21)01210-1","journal-title":"Lancet"},{"key":"4525_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/VPDT7105","volume":"27","author":"S Banerjee","year":"2023","unstructured":"Banerjee S, Farina N, Henderson C, High J, Stirling S, Shepstone L, Fountain J, Ballard C, Bentham P, Burns A, Fox C (2023) A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer\u2019s disease and agitated behaviours: the HTA-SYMBAD trial. Health Technol Assess 27:1\u2013108. https:\/\/doi.org\/10.3310\/VPDT7105","journal-title":"Health Technol Assess"},{"key":"4525_CR19","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1080\/01616412.2019.1580462","volume":"41","author":"E Bektur","year":"2019","unstructured":"Bektur E, \u015eahin E, Ceyhan E, Donmez DB, Canbek M, Baycu C, Can OD (2019a) Beneficial effect of mirtazapine on diabetes-induced hyperalgesia: involvement of TRPV1 and ASIC1 channels in the spinal cord and dorsal root ganglion. Neurol Res 41:544\u2013553. https:\/\/doi.org\/10.1080\/01616412.2019.1580462","journal-title":"Neurol Res"},{"key":"4525_CR20","doi-asserted-by":"publisher","unstructured":"Bektur E, Sahin E, Baycu C (2019) Mirtazapine may show anti-hyperglycemic effect by decreasing GLUT2 through leptin and galanin expressions in the liver of type 1 diabetic ratsIran.\u00a0J Basic Med\u00a0Sci 22:676. https:\/\/doi.org\/10.22038\/ijbms.2019.34529.8190","DOI":"10.22038\/ijbms.2019.34529.8190"},{"key":"4525_CR21","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1517\/14656566.2011.585459","volume":"12","author":"S Benjamin","year":"2011","unstructured":"Benjamin S, Doraiswamy PM (2011) Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother 12:1623\u20131632. https:\/\/doi.org\/10.1517\/14656566.2011.585459","journal-title":"Expert Opin Pharmacother"},{"key":"4525_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.copsyc.2017.01.003","volume":"14","author":"NC Bernardy","year":"2017","unstructured":"Bernardy NC, Friedman MJ (2017) Pharmacological management of posttraumatic stress disorder. Curr Opin Psychol 14:116\u2013121. https:\/\/doi.org\/10.1016\/j.copsyc.2017.01.003","journal-title":"Curr Opin Psychol"},{"key":"4525_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.psy.50.4.383","volume":"50","author":"KM Brintzenhofe-Szoc","year":"2009","unstructured":"Brintzenhofe-Szoc KM, Levin TT, Li Y, Kissane DW, Zabora JR (2009) Mixed anxiety\/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosom 50:383\u2013391. https:\/\/doi.org\/10.1176\/appi.psy.50.4.383","journal-title":"Psychosom"},{"key":"4525_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/15360288.2020.1734142","volume":"34","author":"H Bromberg","year":"2020","unstructured":"Bromberg H, Chang Y, Craig D (2020) Pruritic manifestation of peripheral t cell lymphoma effectively managed with mirtazapine: a case report. J Pain Palliat Care Pharmacother 34:153\u2013154. https:\/\/doi.org\/10.1080\/15360288.2020.1734142","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"4525_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/CLEP.S40245","volume":"6","author":"C Canavan","year":"2014","unstructured":"Canavan C, West J, Card T (2014) The epidemiology of irritable bowel syndrome. Clin Epidemiol 6:71\u201380. https:\/\/doi.org\/10.2147\/CLEP.S40245","journal-title":"Clin Epidemiol"},{"key":"4525_CR26","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10637-020-00903-8","volume":"38","author":"J Cao","year":"2020","unstructured":"Cao J, Ouyang Q, Wang S, Ragaz J, Wang X, Teng Y, Wang B, Wang Z, Zhang J, Wang L, Wu J (2020) Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial. Invest New Drugs 38:507\u2013514. https:\/\/doi.org\/10.1007\/s10637-020-00903-8","journal-title":"Invest New Drugs"},{"key":"4525_CR27","doi-asserted-by":"publisher","unstructured":"Chaudhary A, Nagaich U, Gulati N, Sharma VK, Khosa RL, Partapur MU (2012) Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications: A recent review. J Adv Pharm Educ Res 2:32\u201367.https:\/\/doi.org\/10.5402\/2012\/195727","DOI":"10.5402\/2012\/195727"},{"key":"4525_CR28","doi-asserted-by":"publisher","unstructured":"Chauhan HY, Pai KK (2019) Two birds with one stone: How depression and distress in diabetes respond to antidepressants. Arch Psychiatry and Psychother 2:41\u201347. https:\/\/doi.org\/10.12740\/APP\/103602","DOI":"10.12740\/APP\/103602"},{"key":"4525_CR29","doi-asserted-by":"publisher","first-page":"26802","DOI":"10.4088\/PCC.14l01725","volume":"17","author":"CY Cheng","year":"2015","unstructured":"Cheng CY, Shen YC (2015) Catatonia in psychotic depression associated with bereavement. The Prim Care Companion CNS Disord 17:26802. https:\/\/doi.org\/10.4088\/PCC.14l01725","journal-title":"The Prim Care Companion CNS Disord"},{"key":"4525_CR30","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1093\/jjco\/hyae009","volume":"54","author":"IH Chowdhury","year":"2024","unstructured":"Chowdhury IH, Rahman MS, Chowdhury MN, Afroze YJ, Tabassum M, Marnush M, Zerin N (2024) Mirtazapine versus megestrol acetate in treatment of anorexia-cachexia in advanced cancer patients: a randomized, double-blind trial. Jpn J Clin Oncol 54:530\u2013536. https:\/\/doi.org\/10.1093\/jjco\/hyae009","journal-title":"Jpn J Clin Oncol"},{"key":"4525_CR31","doi-asserted-by":"publisher","first-page":"109102","DOI":"10.1016\/j.yebeh.2023.109102","volume":"140","author":"CS Chu","year":"2023","unstructured":"Chu CS, Lee FL, Bai YM, Su TP, Tsai SJ, Chen TJ, Hsu JW, Chen MH, Liang CS (2023) Antidepressant drugs use and epilepsy risk: a nationwide nested case-control study. Epilepsy Behav Rep 140:109102. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109102","journal-title":"Epilepsy Behav Rep"},{"key":"4525_CR32","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1017\/S003329171700349X","volume":"48","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Williams T, Nikolakopoulou A, Salanti G, Chaimani A, Ipser J, Cowen PJ, Geddes JR, Stein DJ (2018) Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Psychol Med 48:1975\u20131984. https:\/\/doi.org\/10.1017\/S003329171700349X","journal-title":"Psychol Med"},{"key":"4525_CR33","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3390\/ph14090930","volume":"14","author":"AS Correia","year":"2021","unstructured":"Correia AS, Vale N (2021) Antidepressants in Alzheimer\u2019s disease: a focus on the role of mirtazapine. Pharmaceuticals 14:930. https:\/\/doi.org\/10.3390\/ph14090930","journal-title":"Pharmaceuticals"},{"key":"4525_CR34","doi-asserted-by":"publisher","unstructured":"Davis MP (2020) Mirtazapine and Depressions. In: Riederer P, Laux G, Mulsant B, LeW, Nagatsu T, Editors. NeuroPsychopharmacotherapy. Springer, Cham pp. 1\u201329 https:\/\/doi.org\/10.1007\/978-3-319-56015-1_102-1","DOI":"10.1007\/978-3-319-56015-1_102-1"},{"key":"4525_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/13651501.2024.2409654","volume":"28","author":"D De Donatis","year":"2024","unstructured":"De Donatis D, Verrastro M, Fanelli G, Fabbri C, Maniscalco I, Hart X, Schoretsanitis G, Mercolini L, Ferri R, Lanuzza B, Serretti A (2024) Mirtazapine blood levels and antidepressant response. Int J Psychiatry Clin Pract 28:102\u2013106. https:\/\/doi.org\/10.1080\/13651501.2024.2409654","journal-title":"Int J Psychiatry Clin Pract"},{"key":"4525_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2165\/00044011-199815010-00006","volume":"15","author":"LP Delbressine","year":"1998","unstructured":"Delbressine LP, Moonen ME, Kaspersen FM, Wagenaars GN, Jacobs PL, Timmer CJ, Paanakker JE, Van Hal HJ, Voortman G (1998) Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Investig 15:45\u201355. https:\/\/doi.org\/10.2165\/00044011-199815010-00006","journal-title":"Clin Drug Investig"},{"key":"4525_CR37","unstructured":"Dizaj, S. Maleki, Zh Vazifehasl, S. Salatin, Kh Adibkia, and Y. Javadzadeh (2015) Nanosizing of drugs: effect on dissolution rate. RPS 10:95\u2013108\u00a0https:\/\/journals.lww.com\/rips\/toc\/2015\/10020"},{"key":"4525_CR38","doi-asserted-by":"publisher","unstructured":"El Sisi AM, Eissa EM, Hassan AH, Bekhet MA, El-Ela FI, Roh EJ, Kharshoum RM, Ali AA (2025) Nose-to-Brain Delivery of Chitosan-Grafted Leciplexes for Promoting the Bioavailability and Antidepressant Efficacy of Mirtazapine: In Vitro Assessment and Animal Studies. Pharma 18:46\u00a0https:\/\/doi.org\/10.3390\/ph18010046","DOI":"10.3390\/ph18010046"},{"key":"4525_CR39","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1007\/s13346-024-01525-w","volume":"14","author":"SN El-Helaly","year":"2024","unstructured":"El-Helaly SN, Rashad AA (2024) Mirtazapine loaded polymeric micelles for rapid release tablet: a novel formulation\u2014In vitro and in vivo studies. Drug Deliv Transl Res 14:2488\u20132498. https:\/\/doi.org\/10.1007\/s13346-024-01525-w","journal-title":"Drug Deliv Transl Res"},{"key":"4525_CR40","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.biopha.2017.09.022","volume":"95","author":"AE El-Sisi","year":"2017","unstructured":"El-Sisi AE, El-Sayad ME, Abdelsalam NM (2017) Protective effects of mirtazapine and chrysin on experimentally induced testicular damage in rats. Biomed Pharmacother 95:1059\u20131066. https:\/\/doi.org\/10.1016\/j.biopha.2017.09.022","journal-title":"Biomed Pharmacother"},{"key":"4525_CR41","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4236\/pp.2015.610049","volume":"6","author":"KE Ezealisiji","year":"2015","unstructured":"Ezealisiji KE, Mbah CJ, Osadebe PO (2015) Aqueous solubility enhancement of mirtazapine: effect of cosolvent and surfactant. Pharmacol & Pharm 6:471\u2013476. https:\/\/doi.org\/10.4236\/pp.2015.610049","journal-title":"Pharmacol & Pharm"},{"key":"4525_CR42","doi-asserted-by":"publisher","first-page":"661728","DOI":"10.3389\/fnmol.2021.661728","volume":"14","author":"E Fabbretti","year":"2021","unstructured":"Fabbretti E, Antognolli G, Tongiorgi E (2021) Amyloid-\u03b2 impairs dendritic trafficking of Golgi-like organelles in the early phase preceding neurite atrophy: rescue by mirtazapine. Front Mol Neurosci 14:661728. https:\/\/doi.org\/10.3389\/fnmol.2021.661728","journal-title":"Front Mol Neurosci"},{"key":"4525_CR43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/ani12020155","volume":"12","author":"L Ferro","year":"2022","unstructured":"Ferro L, Ciccarelli S, Stanzani G, Nappi L, Angelini F, Leo C (2022) Appetite stimulant and anti-emetic effect of mirtazapine transdermal ointment in cats affected by lymphoma following chemotherapy administration: a multi-centre retrospective study. Animals 12:155. https:\/\/doi.org\/10.3390\/ani12020155","journal-title":"Animals"},{"key":"4525_CR44","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3390\/gels9060457","volume":"9","author":"M Ghazwani","year":"2023","unstructured":"Ghazwani M, Vasudevan R, Kandasamy G, Manusri N, Devanandan P, Puvvada RC, Veeramani VP, Paulsamy P, Venkatesan K, Chidmabaram K, Dhurke R (2023) Formulation of intranasal mucoadhesive thermotriggered in situ gel containing mirtazapine as an antidepressant drug. Gels 9:457. https:\/\/doi.org\/10.3390\/gels9060457","journal-title":"Gels"},{"key":"4525_CR45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1353-8020(02)00011-1","volume":"9","author":"PH Gordon","year":"2002","unstructured":"Gordon PH, Pullman SL, Louis ED, Frucht SJ, Fahn S (2002) Mirtazapine in Parkinsonian tremor. Parkinsonism Relat Disord 9:125\u2013126. https:\/\/doi.org\/10.1016\/S1353-8020(02)00011-1","journal-title":"Parkinsonism Relat Disord"},{"key":"4525_CR46","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.pjnns.2018.07.005","volume":"52","author":"N G\u00f3rska","year":"2018","unstructured":"G\u00f3rska N, S\u0142upski J, Cuba\u0142a WJ, Wiglusz MS, Ga\u0142uszko-W\u0119gielnik M (2018) Antidepressants in epilepsy. Neurol Neurochir Pol 52:657\u2013661. https:\/\/doi.org\/10.1016\/j.pjnns.2018.07.005","journal-title":"Neurol Neurochir Pol"},{"key":"4525_CR47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fpsyt.2021.638651","volume":"27","author":"Y Haasum","year":"2016","unstructured":"Haasum Y, Fastbom J, Johnell K (2016) Use of antidepressants in Parkinson\u2019s disease: a Swedish register-based study of over 1.5 million older people. Parkinsonism Relat Disord 27:85\u201388. https:\/\/doi.org\/10.3389\/fpsyt.2021.638651","journal-title":"Parkinsonism Relat Disord"},{"key":"4525_CR48","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00213-017-4530-z","volume":"234","author":"A Hamadjida","year":"2017","unstructured":"Hamadjida A, Nuara SG, Veyres N, Frouni I, Kwan C, Sid-Otmane L, Harraka MJ, Gourdon JC, Huot P (2017) The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset. Psychopharmacol 234:905\u2013911. https:\/\/doi.org\/10.1007\/s00213-017-4530-z","journal-title":"Psychopharmacol"},{"key":"4525_CR49","doi-asserted-by":"publisher","unstructured":"Hamed HE, Hussein AA (2020) Preparation, in vitro and ex-vivo evaluation of mirtazapine nanosuspension and nanoparticles incorporated in orodispersible tablets. Iraqi J Pharm Sci 29:62\u201375\u00a0https:\/\/doi.org\/10.31351\/vol29iss1pp62-75","DOI":"10.31351\/vol29iss1pp62-75"},{"key":"4525_CR50","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"MA Hamilton","year":"1959","unstructured":"Hamilton MA (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50\u201355. https:\/\/doi.org\/10.1111\/j.2044-8341.1959.tb00467.x","journal-title":"Br J Med Psychol"},{"key":"4525_CR51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56. https:\/\/doi.org\/10.1136\/jnnp.23.1.56","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4525_CR52","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1007\/s00210-023-02818-6","volume":"397","author":"EH Hassanein","year":"2024","unstructured":"Hassanein EH, Althagafy HS, Baraka MA, Abd-Alhameed EK, Ibrahim IM (2024) Pharmacological update of mirtazapine: a narrative literature review. Naunyn-Schmiedebergs Arch Pharmacol 397:2603\u20132619. https:\/\/doi.org\/10.1007\/s00210-023-02818-6","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"4525_CR53","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40263-013-0062-1","volume":"27","author":"M He","year":"2013","unstructured":"He M, Deng C, Huang XF (2013) The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. CNS Drugs 27:423\u2013434. https:\/\/doi.org\/10.1007\/s40263-013-0062-1","journal-title":"CNS Drugs"},{"key":"4525_CR54","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mds.20324","volume":"20","author":"MA Hely","year":"2005","unstructured":"Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney multicenter study of Parkinson\u2019s disease: non-L-dopa\u2013responsive problems dominate at 15 years. Mov Disord 20:190\u2013199. https:\/\/doi.org\/10.1002\/mds.20324","journal-title":"Mov Disord"},{"key":"4525_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11920-017-0825-3","volume":"19","author":"RJ Herringa","year":"2017","unstructured":"Herringa RJ (2017) Trauma, PTSD, and the developing brain. Curr Psychiatry Rep 19:1\u20139. https:\/\/doi.org\/10.1007\/s11920-017-0825-3","journal-title":"Curr Psychiatry Rep"},{"key":"4525_CR56","unstructured":"https:\/\/clinicaltrials.gov\/search?cond=Mirtazapine%20. Accessed on 17th July, 2025"},{"key":"4525_CR57","unstructured":"https:\/\/worldwide.espacenet.com\/patent\/search?q=mirtazapine Accessed on 17th July, 2025"},{"key":"4525_CR58","doi-asserted-by":"publisher","first-page":"959","DOI":"10.4088\/jcp.v65n0712","volume":"65","author":"EM Hunkeler","year":"2004","unstructured":"Hunkeler EM, Ming E, Lee JY, Fireman B, Markson LE (2004) Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 65:959\u2013965. https:\/\/doi.org\/10.4088\/jcp.v65n0712","journal-title":"J Clin Psychiatry"},{"key":"4525_CR59","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jpainsymman.2021.05.017","volume":"62","author":"CN Hunter","year":"2021","unstructured":"Hunter CN, Abdel-Aal HH, Elsherief WA, Farag DE, Riad NM, Alsirafy SA (2021) Mirtazapine in cancer-associated anorexia and cachexia: a double-blind placebo-controlled randomized trial. J Pain Symptom Manage 62:1207\u20131215. https:\/\/doi.org\/10.1016\/j.jpainsymman.2021.05.017","journal-title":"J Pain Symptom Manage"},{"key":"4525_CR60","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/03639045.2024.2313538","volume":"50","author":"LM Hussein","year":"2024","unstructured":"Hussein LM, Dawaba AM, El-Adawy SA (2024) Formulation, optimization and full characterization of mirtazapine loaded aquasomes: a new technique to boost antidepressant effects. Drug Dev Ind Pharm 50:206\u2013222. https:\/\/doi.org\/10.1080\/03639045.2024.2313538","journal-title":"Drug Dev Ind Pharm"},{"key":"4525_CR61","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1007\/s13346-024-01528-7","volume":"14","author":"MM Ibrahim","year":"2024","unstructured":"Ibrahim MM, Basalious EB, El-Nabarawi MA, Makhlouf AI, Sayyed ME, Ibrahim IT (2024a) Nose to brain delivery of mirtazapine via lipid nanocapsules: Preparation, statistical optimization, radiolabeling, in vivo biodistribution and pharmacokinetic study. Drug Deliv Transl Res 14:2539\u20132557. https:\/\/doi.org\/10.1007\/s13346-024-01528-7","journal-title":"Drug Deliv Transl Res"},{"key":"4525_CR62","doi-asserted-by":"publisher","first-page":"105395","DOI":"10.1016\/j.jddst.2024.105395","volume":"92","author":"TM Ibrahim","year":"2024","unstructured":"Ibrahim TM, Abdulla NA, Mohamed MA (2024b) Investigating the efficacy of mirtazapine-embedded invasomal gel nanocarriers via I-optimal design for management of atopic dermatitis. J Drug Deliv Sci Technol 92:105395. https:\/\/doi.org\/10.1016\/j.jddst.2024.105395","journal-title":"J Drug Deliv Sci Technol"},{"key":"4525_CR63","unstructured":"Jilani TN, Gibbons JR, Faizy RM, Faizy RM, Saadabadi A (2025) Mirtazapine. [Updated 2024 Nov 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519059\/. Accessed 16th June 2025."},{"key":"4525_CR64","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.cvsm.2019.04.008","volume":"49","author":"CM Johannes","year":"2019","unstructured":"Johannes CM, Musser ML (2019) Anorexia and the cancer patient. Veterinary Clinics: Small Anim Pract 49:837\u2013854. https:\/\/doi.org\/10.1016\/j.cvsm.2019.04.008","journal-title":"Veterinary Clinics: Small Anim Pract"},{"key":"4525_CR65","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12916-022-02247-x","volume":"20","author":"RM Joseph","year":"2022","unstructured":"Joseph RM, Jack RH, Morriss R, Knaggs RD, Butler D, Hollis C, Hippisley-Cox J, Coupland C (2022) The risk of all-cause and cause-specific mortality in people prescribed mirtazapine: an active comparator cohort study using electronic health records. BMC Med 20:43. https:\/\/doi.org\/10.1186\/s12916-022-02247-x","journal-title":"BMC Med"},{"key":"4525_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2202-15-79","volume":"15","author":"N Kadoguchi","year":"2014","unstructured":"Kadoguchi N, Okabe S, Yamamura Y, Shono M, Fukano T, Tanabe A, Yokoyama H, Kasahara J (2014) Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced mice model of Parkinson\u2019s disease. BMC Neurosci 15:1\u20132. https:\/\/doi.org\/10.1186\/1471-2202-15-79","journal-title":"BMC Neurosci"},{"key":"4525_CR67","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12888-024-06396-6","volume":"25","author":"CB Kamp","year":"2025","unstructured":"Kamp CB, Petersen JJ, Faltermeier P, Juul S, Sillassen CD, Siddiqui F, Andersen RK, Moncrieff J, Horowitz MA, Hengartner MP, Kirsch I (2025) The risks of adverse events with mirtazapine for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis. BMC Psychiatry 25:67. https:\/\/doi.org\/10.1186\/s12888-024-06396-6","journal-title":"BMC Psychiatry"},{"key":"4525_CR68","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.euroneuro.2018.01.007","volume":"28","author":"R Kaur","year":"2018","unstructured":"Kaur R, Sinha VR (2018) Antidepressants as antipruritic agents: a review. Eur Neuropsychopharmacol 28:341\u2013352. https:\/\/doi.org\/10.1016\/j.euroneuro.2018.01.007","journal-title":"Eur Neuropsychopharmacol"},{"key":"4525_CR69","doi-asserted-by":"publisher","first-page":"119439","DOI":"10.1016\/j.ijpharm.2020.119439","volume":"586","author":"R Kaur","year":"2020","unstructured":"Kaur R, Sharma N, Tikoo K, Sinha VR (2020) Development of mirtazapine loaded solid lipid nanoparticles for topical delivery: optimization, characterization and cytotoxicity evaluation. Int J Pharm 586:119439. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119439","journal-title":"Int J Pharm"},{"key":"4525_CR70","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/medicines6030073","volume":"6","author":"R Khanna","year":"2019","unstructured":"Khanna R, Boozalis E, Belzberg M, Zampella JG, Kwatra SG (2019) Mirtazapine for the treatment of chronic pruritus. Medicines (Basel) 6:73. https:\/\/doi.org\/10.3390\/medicines6030073","journal-title":"Medicines (Basel)"},{"key":"4525_CR71","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1177\/1535370215576304","volume":"240","author":"NF Khedr","year":"2015","unstructured":"Khedr NF (2015) Protective effect of mirtazapine and hesperidin on cyclophosphamide-induced oxidative damage and infertility in rat ovaries. Exp Biol Med 240:1682\u20131689. https:\/\/doi.org\/10.1177\/1535370215576304","journal-title":"Exp Biol Med"},{"key":"4525_CR72","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jddst.2017.10.012","volume":"43","author":"H Koradia","year":"2018","unstructured":"Koradia H, Chaudhari K (2018) Formulation of unidirectional buccal tablet of Mirtazapine: an in vitro and ex vivo evaluation. J Drug Deliv Sci Technol 43:233\u2013242. https:\/\/doi.org\/10.1016\/j.jddst.2017.10.012","journal-title":"J Drug Deliv Sci Technol"},{"key":"4525_CR73","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/IJGM.S93698","volume":"9","author":"BE Lacy","year":"2016","unstructured":"Lacy BE (2016) Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome. Int J Gen Med 9:7\u201317. https:\/\/doi.org\/10.2147\/IJGM.S93698","journal-title":"Int J Gen Med"},{"key":"4525_CR74","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1353-8020(02)00011-1","volume":"129","author":"G Laux","year":"2022","unstructured":"Laux G (2022) Parkinson and depression: review and outlook. J Neural Transm 129:601\u2013608. https:\/\/doi.org\/10.1016\/S1353-8020(02)00011-1","journal-title":"J Neural Transm"},{"key":"4525_CR75","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/ijms17030425","volume":"17","author":"MJ Lavery","year":"2016","unstructured":"Lavery MJ, Stull C, Kinney MO, Yosipovitch G (2016) Nocturnal pruritus: the battle for a peaceful night\u2019s sleep. Int J Mol Sci 17:425. https:\/\/doi.org\/10.3390\/ijms17030425","journal-title":"Int J Mol Sci"},{"key":"4525_CR76","doi-asserted-by":"publisher","unstructured":"Lech MA, Kaminska K, Wasik A, Lorenc-Koci E, Rogoz Z (2021) Repeated co-treatment with mirtazapine and aripiprazole reversed the schizophrenia-like behaviors and increased the brain-derived neurotrophic factor mRNA expression in the adult Sprague-Dawley rats exposed to glutathione deficit during early postnatal brain development. J Physiol\u00a0Pharmacol 72:699\u2013709. https:\/\/doi.org\/10.26402\/jpp.2021.5.05","DOI":"10.26402\/jpp.2021.5.05"},{"key":"4525_CR77","doi-asserted-by":"publisher","first-page":"106087","DOI":"10.1016\/j.tvjl.2024.106087","volume":"304","author":"CH Lee","year":"2024","unstructured":"Lee CH, Wang SL (2024) Oral mirtazapine decreases the gastrointestinal adverse effects in cats on doxorubicin chemotherapy. Vet J 304:106087. https:\/\/doi.org\/10.1016\/j.tvjl.2024.106087","journal-title":"Vet J"},{"key":"4525_CR78","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1477-7827-8-51","volume":"8","author":"CN Lemos","year":"2010","unstructured":"Lemos CN, Reis FM, Pena GN, Silveira LC, Camargos AF (2010) Assessment of fertility protection and ovarian reserve with GnRH antagonist in rats undergoing chemotherapy with cyclophosphamide. Reprod Biol Endocrinol 8:51. https:\/\/doi.org\/10.1186\/1477-7827-8-51","journal-title":"Reprod Biol Endocrinol"},{"key":"4525_CR79","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s43440-019-00009-w","volume":"72","author":"V Lieberknecht","year":"2020","unstructured":"Lieberknecht V, Engel D, Rodrigues AL, Gabilan NH (2020) Neuroprotective effects of mirtazapine and imipramine and their effect in pro-and anti-apoptotic gene expression in human neuroblastoma cells. Pharmacol Rep 72:563\u2013570. https:\/\/doi.org\/10.1007\/s43440-019-00009-w","journal-title":"Pharmacol Rep"},{"key":"4525_CR80","doi-asserted-by":"publisher","unstructured":"Loke, Ying Hui, Yik-Ling Chew, Ashok Kumar Janakiraman, Siew-Keah Lee, ABM Helal Uddin, Choon Fu Goh, Phei Er Kee, Hui Suan Ng, Long Chiau Ming, and Kai Bin Liew (2024) Development of a novel direct compressible co-processed excipient and its application for formulation of Mirtazapine orally disintegrating tablets. Drug Dev Ind Pharm 50:36\u201344.https:\/\/doi.org\/10.1080\/03639045.2023.2294095","DOI":"10.1080\/03639045.2023.2294095"},{"key":"4525_CR81","doi-asserted-by":"publisher","first-page":"505","DOI":"10.5056\/jnm19166","volume":"26","author":"J Lu","year":"2020","unstructured":"Lu J, Shi L, Huang D, Fan W, Li X, Zhu L, Wei J, Fang X (2020) Depression and structural factors are associated with symptoms in patients of irritable bowel syndrome with diarrhea. Neurogastroenterol Motil 26:505. https:\/\/doi.org\/10.5056\/jnm19166","journal-title":"Neurogastroenterol Motil"},{"key":"4525_CR82","doi-asserted-by":"publisher","first-page":"451","DOI":"10.22037\/ijpr.2020.113955.14584","volume":"19","author":"A Maleki","year":"2020","unstructured":"Maleki A, Ghadiyani M, Salamzadeh J, Salari S, Banihashem S, Tavakoli-Ardakani M (2020) Comparison of mirtazapine and olanzapine on nausea and vomiting following anthracycline-cyclophosphamide chemotherapy regimen in patients with breast cancer. Iran J Pharm Res 19:451. https:\/\/doi.org\/10.22037\/ijpr.2020.113955.14584","journal-title":"Iran J Pharm Res"},{"key":"4525_CR83","doi-asserted-by":"publisher","unstructured":"Maqbool, A., Aamir, M. N., & Naeem, M. (2022) Formulation and evaluation of fast dissolving films embedded with nanoparticles of mirtazapine hydrochloride. J Contemp Pharm 6:6\u201318.https:\/\/doi.org\/10.56770\/jcp2022612","DOI":"10.56770\/jcp2022612"},{"key":"4525_CR84","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1095\/biolreprod.111.091173","volume":"85","author":"CJ Mark-Kappeler","year":"2011","unstructured":"Mark-Kappeler CJ, Hoyer PB, Devine PJ (2011) Xenobiotic effects on ovarian preantral follicles. Biol Reprod 85:871\u2013883. https:\/\/doi.org\/10.1095\/biolreprod.111.091173","journal-title":"Biol Reprod"},{"key":"4525_CR85","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/WNF.0000000000000384","volume":"26","author":"G Meco","year":"2003","unstructured":"Meco G, Fabrizio E, Di Rezze S, Alessandri A, Pratesi L (2003) Mirtazapine in L-dopa-induced dyskinesias. Clin Neuropharmacol 26:179\u2013181. https:\/\/doi.org\/10.1097\/WNF.0000000000000384","journal-title":"Clin Neuropharmacol"},{"key":"4525_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40473-025-00308-y","volume":"12","author":"A Mehra","year":"2025","unstructured":"Mehra A, Khanna J, Singh G, Sachdeva V, Bedi N (2025) A comprehensive review on major depressive disorder: exploring etiology, pathogenesis and clinical approaches. Curr Behav Neurosci Rep 12:1\u201334. https:\/\/doi.org\/10.1007\/s40473-025-00308-y","journal-title":"Curr Behav Neurosci Rep"},{"key":"4525_CR87","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S246393","author":"M Mehrpooya","year":"2020","unstructured":"Mehrpooya M, Gholyaf M, Yasrebifar F, Mohammadi Y, Sheikh V (2020) Evaluation of efficacy of mirtazapine on pruritus and serum histamine and serotonin levels in patients undergoing hemodialysis: a before-after pilot clinical trial. Int J Nephrol Renovasc Dis. https:\/\/doi.org\/10.2147\/IJNRD.S246393","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"4525_CR88","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X20988408","volume":"9","author":"Y Miyahara","year":"2021","unstructured":"Miyahara Y, Haruta-Tsukamoto A, Funahashi H, Matsuo H, Kanemaru-Kawazoe A, Nishimori T, Ishida Y (2021) Differential onset time of mirtazapine on pruritus and depression in a patient receiving hemodialysis. SAGE Open Med Case Rep 9:2050313X20988408. https:\/\/doi.org\/10.1177\/2050313X20988408","journal-title":"SAGE Open Med Case Rep"},{"key":"4525_CR89","doi-asserted-by":"publisher","first-page":"114732","DOI":"10.1016\/j.fct.2024.114732","volume":"189","author":"T Mohammadi","year":"2024","unstructured":"Mohammadi T (2024) Effect of quercetin and mirtazapine on spermatogenesis and testis structure in phenylhydrazine-induced hemolytic anemia mice: an experimental study. Food Chem Toxicol 189:114732. https:\/\/doi.org\/10.1016\/j.fct.2024.114732","journal-title":"Food Chem Toxicol"},{"key":"4525_CR90","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/00004850-199512004-00006","volume":"10","author":"SA Montgomery","year":"1995","unstructured":"Montgomery SA (1995) Safety of mirtazapine: a review. Int Clin Psychopharmacol 10:37\u201345. https:\/\/doi.org\/10.1097\/00004850-199512004-00006","journal-title":"Int Clin Psychopharmacol"},{"key":"4525_CR91","doi-asserted-by":"publisher","first-page":"112701","DOI":"10.1016\/j.psychres.2019.112701","volume":"284","author":"S Moodliar","year":"2020","unstructured":"Moodliar S, Naguy A, Elsori DH (2020) Add-on mirtazapine to clozapine-responsive early-onset schizophrenia. Psychiatry Res 284:112701. https:\/\/doi.org\/10.1016\/j.psychres.2019.112701","journal-title":"Psychiatry Res"},{"key":"4525_CR92","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/14656566.2018.1543402","volume":"20","author":"M Mula","year":"2019","unstructured":"Mula M, Sander JW (2019) Current and emerging drug therapies for the treatment of depression in adults with epilepsy. Expert Opin Pharmacother 20:41\u201345. https:\/\/doi.org\/10.1080\/14656566.2018.1543402","journal-title":"Expert Opin Pharmacother"},{"key":"4525_CR93","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1080\/10717544.2022.2075985","volume":"29","author":"AA Musallam","year":"2022","unstructured":"Musallam AA, Mahdy MA, Elnahas HM (2022) Aldeeb RA (2018) Optimization of mirtazapine loaded into mesoporous silica nanostructures via Box-Behnken design: in-vitro characterization and in-vivo assessment. Drug Deliv 29:1582\u20131594. https:\/\/doi.org\/10.1080\/10717544.2022.2075985","journal-title":"Drug Deliv"},{"key":"4525_CR94","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.5530\/ijper.54.2s.77","volume":"54","author":"WR Naresh","year":"2020","unstructured":"Naresh WR, Dilip DV, Sunil KP (2020) Xyloglucan based nasal in situ gel formulation of mirtazapine for treatment of depression. Indian J Pharm Educ Res 54:S210\u2013S219. https:\/\/doi.org\/10.5530\/ijper.54.2s.77","journal-title":"Indian J Pharm Educ Res"},{"key":"4525_CR95","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.3390\/molecules27134005","volume":"27","author":"F Naureen","year":"2022","unstructured":"Naureen F, Shah Y, Shah SI, Abbas M, Rehman IU, Muhammad S, Goh KW, Khuda F, Khan A, Chan SY, Mushtaq M (2022) Formulation development of mirtazapine liquisolid compacts: optimization using central composite design. Molecules 27:4005. https:\/\/doi.org\/10.3390\/molecules27134005","journal-title":"Molecules"},{"key":"4525_CR96","doi-asserted-by":"publisher","first-page":"17138","DOI":"10.1074\/jbc.RA120.014420","volume":"295","author":"T Oba","year":"2020","unstructured":"Oba T, Saito T, Asada A, Shimizu S, Iijima KM, Ando K (2020) Microtubule affinity\u2013regulating kinase 4 with an Alzheimer\u2019s disease-related mutation promotes tau accumulation and exacerbates neurodegeneration. J Biol Chem 295:17138\u201317147. https:\/\/doi.org\/10.1074\/jbc.RA120.014420","journal-title":"J Biol Chem"},{"key":"4525_CR97","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/hup.929","volume":"23","author":"NK Ozmenler","year":"2008","unstructured":"Ozmenler NK, Karlidere T, Bozkurt A, Yetkin S, Doruk A, Sutcigil L, Cansever A, Uzun O, Ozgen F, Ozsahin A (2008) Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors. Hum Psychopharmacol 23:321\u2013326. https:\/\/doi.org\/10.1002\/hup.929","journal-title":"Hum Psychopharmacol"},{"key":"4525_CR98","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.genhosppsych.2014.09.002","volume":"37","author":"S Ozsoy","year":"2015","unstructured":"Ozsoy S, Besirli A, Unal D, Abdulrezzak U, Orhan O (2015) The association between depression, weight loss and leptin\/ghrelin levels in male patients with head and neck cancer undergoing radiotherapy. Gen Hosp Psychiatry 37:31\u201335. https:\/\/doi.org\/10.1016\/j.genhosppsych.2014.09.002","journal-title":"Gen Hosp Psychiatry"},{"key":"4525_CR99","doi-asserted-by":"publisher","first-page":"e9863","DOI":"10.7759\/cureus.9863","volume":"12","author":"RS Patel","year":"2020","unstructured":"Patel RS, Veluri N, Verma G (2020) Mirtazapine creating \u201cmiracles\u201d in psychotic depression with catatonia. Cureus 12:e9863. https:\/\/doi.org\/10.7759\/cureus.9863","journal-title":"Cureus"},{"key":"4525_CR100","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40265-017-0746-9","volume":"77","author":"MP Pereira","year":"2017","unstructured":"Pereira MP, St\u00e4nder S (2017) Chronic pruritus: current and emerging treatment options. Drugs 77:999\u20131007. https:\/\/doi.org\/10.1007\/s40265-017-0746-9","journal-title":"Drugs"},{"key":"4525_CR101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011943.pub2","author":"LA Perry","year":"2018","unstructured":"Perry LA, Ramson D, Stricklin S (2018) Mirtazapine adjunct for people with schizophrenia. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD011943.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"4525_CR102","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ijwd.2021.02.010","volume":"7","author":"I Podder","year":"2021","unstructured":"Podder I, Mondal H, Kroumpouzos G (2021) Nocturnal pruritus and sleep disturbance associated with dermatologic disorders in adult patients. Int J Womens Dermatol 7:403\u2013410. https:\/\/doi.org\/10.1016\/j.ijwd.2021.02.010","journal-title":"Int J Womens Dermatol"},{"key":"4525_CR103","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1186\/1471-2202-15-79","volume":"29","author":"GM Pontone","year":"2021","unstructured":"Pontone GM, Mills KA (2021) Optimal treatment of depression and anxiety in Parkinson\u2019s disease. Am J Geriatr Psychiatry 29:530\u2013540. https:\/\/doi.org\/10.1186\/1471-2202-15-79","journal-title":"Am J Geriatr Psychiatry"},{"key":"4525_CR104","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s12272-011-1112-1","volume":"34","author":"OP Ranjan","year":"2011","unstructured":"Ranjan OP, Shavi GV, Nayak UY, Arumugam K, Averineni RK, Meka SR, Sureshwar P (2011) Controlled release chitosan microspheres of mirtazapine: in vitro and in vivo evaluation. Arch Pharm Res 34:1919\u20131929. https:\/\/doi.org\/10.1007\/s12272-011-1112-1","journal-title":"Arch Pharm Res"},{"key":"4525_CR105","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00406-020-01223-x","volume":"271","author":"MA Reinhard","year":"2021","unstructured":"Reinhard MA, Seifert J, Greiner T, Toto S, Bleich S, Grohmann R (2021) Pharmacotherapy of 1,044 inpatients with posttraumatic stress disorder: current status and trends in German-speaking countries. Eur Arch Psychiatry Clin Neurosci 271:1065\u20131076. https:\/\/doi.org\/10.1007\/s00406-020-01223-x","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"4525_CR106","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/exd.13959","volume":"28","author":"R Reszke","year":"2019","unstructured":"Reszke R, Szepietowski JC (2019) Can we use psychoactive drugs to treat pruritus? Exp Dermatol 28:1422\u20131431. https:\/\/doi.org\/10.1111\/exd.13959","journal-title":"Exp Dermatol"},{"key":"4525_CR107","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1177\/1049909109345685","volume":"27","author":"RP Riechelmann","year":"2010","unstructured":"Riechelmann RP, Burman D, Tannock IF, Rodin G, Zimmermann C (2010) Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am J Hosp Palliat Med 27:106\u2013110. https:\/\/doi.org\/10.1177\/1049909109345685","journal-title":"Am J Hosp Palliat Med"},{"key":"4525_CR108","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.acthis.2019.01.007","volume":"121","author":"E Sahin","year":"2019","unstructured":"Sahin E, Bektur E, Donmez DB, Baycu C, Can OD, Sahinturk V (2019) Mirtazapine suppresses sterile inflammation through NLRP3-inflammasome in diabetic rat kidney. Acta Histochem 121:289\u2013296. https:\/\/doi.org\/10.1016\/j.acthis.2019.01.007","journal-title":"Acta Histochem"},{"key":"4525_CR109","doi-asserted-by":"publisher","first-page":"17","DOI":"10.29245\/2578-9657\/2018\/3.1120","volume":"3","author":"S Sanagapalli","year":"2018","unstructured":"Sanagapalli S, Kim E, Zarate-Lopez N (2018) Mirtazapine in diarrhea-predominant irritable bowel syndrome: an open-label study. J Gastroenterol Dig Dis 3:17\u201321. https:\/\/doi.org\/10.29245\/2578-9657\/2018\/3.1120","journal-title":"J Gastroenterol Dig Dis"},{"key":"4525_CR110","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.nefroe.2022.02.004","volume":"42","author":"C Santos-Alonso","year":"2022","unstructured":"Santos-Alonso C, Mart\u00edn MM, Villanueva RS, Garc\u00eda L\u00c1, Gallardo MA, Rubio MA, del Peso GG, Gonz\u00e1lez MO, Guti\u00e9rrez RS (2022) Pruritus in dialysis patients. Rev New Perspect Nefrolog\u00eda (English Edition) 42:15\u201321. https:\/\/doi.org\/10.1016\/j.nefroe.2022.02.004","journal-title":"Rev New Perspect Nefrolog\u00eda (English Edition)"},{"key":"4525_CR111","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jpba.2015.03.003","volume":"110","author":"A Sarkar","year":"2015","unstructured":"Sarkar A, Rohani S (2015) Molecular salts and co-crystals of mirtazapine with promising physicochemical properties. J Pharm Biomed Anal 110:93\u201399. https:\/\/doi.org\/10.1016\/j.jpba.2015.03.003","journal-title":"J Pharm Biomed Anal"},{"key":"4525_CR112","doi-asserted-by":"publisher","first-page":"100151","DOI":"10.1016\/j.nxnano.2025.100151","volume":"8","author":"R Satpute","year":"2025","unstructured":"Satpute R, Salve PS, Qutub M, Hussain UMH, Gadge J (2025) Enhanced systemic delivery of mirtazapine through transdermal drug-in-adhesive matrix: a sustained-release approach. Next Nanotechnol 8:100151. https:\/\/doi.org\/10.1016\/j.nxnano.2025.100151","journal-title":"Next Nanotechnol"},{"key":"4525_CR113","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1021\/cn500318q","volume":"6","author":"H Schellekens","year":"2015","unstructured":"Schellekens H, De Francesco PN, Kandil D, Theeuwes WF, McCarthy T, Van Oeffelen WE, Perell\u00f3 M, Giblin L, Dinan TG, Cryan JF (2015) Ghrelin\u2019s orexigenic effect is modulated via a serotonin 2C receptor interaction. ACS Chem Neurosci 6:1186\u20131197. https:\/\/doi.org\/10.1021\/cn500318q","journal-title":"ACS Chem Neurosci"},{"key":"4525_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12668-025-01894-7","volume":"15","author":"AA Shah","year":"2025","unstructured":"Shah AA, Mirza R, Javed A (2025) Brain targeting of mirtazapine via transferosome embedded thermoresponsive nasal gel for sustained release and augmenting bioavailability. BNS 15:1\u201319. https:\/\/doi.org\/10.1007\/s12668-025-01894-7","journal-title":"BNS"},{"key":"4525_CR115","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14581\/jer.17005","volume":"7","author":"RK Sharma","year":"2017","unstructured":"Sharma RK, Singh T, Mishra A, Goel RK (2017) Relative safety of different antidepressants for treatment of depression in chronic epileptic animals associated with depression. J Epilepsy Res 7:25. https:\/\/doi.org\/10.14581\/jer.17005","journal-title":"J Epilepsy Res"},{"key":"4525_CR116","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/WNF.0000000000000384","volume":"43","author":"L Sid-Otmane","year":"2020","unstructured":"Sid-Otmane L, Huot P, Panisset M (2020) Effect of antidepressants on psychotic symptoms in Parkinson disease: a review of case reports and case series. Clin Neuropharmacol 43:61\u201365. https:\/\/doi.org\/10.1097\/WNF.0000000000000384","journal-title":"Clin Neuropharmacol"},{"key":"4525_CR117","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1053\/j.ajkd.2017.05.018","volume":"70","author":"E Simonsen","year":"2017","unstructured":"Simonsen E, Komenda P, Lerner B, Askin N, Bohm C, Shaw J, Tangri N, Rigatto C (2017) Treatment of uremic pruritus: a systematic review. Am J Kidney Dis 70:638\u2013655. https:\/\/doi.org\/10.1053\/j.ajkd.2017.05.018","journal-title":"Am J Kidney Dis"},{"key":"4525_CR118","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s11064-021-03274-5","volume":"46","author":"T Singh","year":"2021","unstructured":"Singh T, Goel RK (2021) Epilepsy associated depression: an update on current scenario, suggested mechanisms, and opportunities. Neurochem Res 46:1305\u20131321. https:\/\/doi.org\/10.1007\/s11064-021-03274-5","journal-title":"Neurochem Res"},{"key":"4525_CR119","doi-asserted-by":"publisher","first-page":"401","DOI":"10.9740\/mhc.2019.11.401","volume":"9","author":"B Spitznogle","year":"2019","unstructured":"Spitznogle B, Gerfin F (2019) Pruritus associated with abrupt mirtazapine discontinuation: single case report. Ment Health Clin 9:401\u2013403. https:\/\/doi.org\/10.9740\/mhc.2019.11.401","journal-title":"Ment Health Clin"},{"key":"4525_CR120","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.cgh.2015.09.043","volume":"14","author":"J Tack","year":"2016","unstructured":"Tack J, Ly HG, Carbone F, Vanheel H, Vanuytsel T, Holvoet L, Boeckxstaens G, Caenepeel P, Arts J, Van Oudenhove L (2016) Efficacy of mirtazapine in patients with functional dyspepsia and weight loss. Clin Gastroenterol Hepatol 14:385\u2013392. https:\/\/doi.org\/10.1016\/j.cgh.2015.09.043","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4525_CR121","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2174\/1570159X20666220627160048","volume":"21","author":"M Tallarico","year":"2023","unstructured":"Tallarico M, Pisano M, Leo A, Russo E, Citraro R, De Sarro G (2023) Antidepressant drugs for seizures and epilepsy: where do we stand? Curr Neuropharmacol 21:1691\u20131713. https:\/\/doi.org\/10.2174\/1570159X20666220627160048","journal-title":"Curr Neuropharmacol"},{"key":"4525_CR122","doi-asserted-by":"publisher","first-page":"pyv049","DOI":"10.1093\/ijnp\/pyv049","volume":"18","author":"V Terevnikov","year":"2015","unstructured":"Terevnikov V, Joffe G, Stenberg JH (2015) Randomized controlled trials of add-on antidepressants in schizophrenia. Int J Neuropsychopharmacol 18:pyv049. https:\/\/doi.org\/10.1093\/ijnp\/pyv049","journal-title":"Int J Neuropsychopharmacol"},{"key":"4525_CR123","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/20415990.2025.2479416","volume":"16","author":"HP Thakkar","year":"2025","unstructured":"Thakkar HP, Unagar A, Goinawala D, Panchal R (2025) Formulation and characterization of Mirtazapine loaded mucoadhesive cubosomal in-situ gel for intranasal delivery. Ther Deliv 16:545\u2013553. https:\/\/doi.org\/10.1080\/20415990.2025.2479416","journal-title":"Ther Deliv"},{"key":"4525_CR124","doi-asserted-by":"publisher","unstructured":"Thomas SG (2000) Irritable bowel syndrome and mirtazapine. Am J Psychiatry 157:1341-a\u00a0https:\/\/doi.org\/10.1176\/appi.ajp.157.8.1341-a","DOI":"10.1176\/appi.ajp.157.8.1341-a"},{"key":"4525_CR125","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1080\/14656566.2020.1854727","volume":"22","author":"M Thomson","year":"2021","unstructured":"Thomson M, Sharma V (2021) Pharmacotherapeutic considerations for the treatment of posttraumatic stress disorder during and after pregnancy. Expert Opin Pharmacother 22:705\u2013714. https:\/\/doi.org\/10.1080\/14656566.2020.1854727","journal-title":"Expert Opin Pharmacother"},{"key":"4525_CR126","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2165\/00003088-200038060-00001","volume":"38","author":"CJ Timmer","year":"2000","unstructured":"Timmer CJ, Sitsen JA, Delbressine LP (2000) Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 38:461\u2013474. https:\/\/doi.org\/10.2165\/00003088-200038060-00001","journal-title":"Clin Pharmacokinet"},{"key":"4525_CR127","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2164\/jandrol.108.005132","volume":"29","author":"TT Turner","year":"2008","unstructured":"Turner TT, Lysiak JJ (2008) Oxidative stress: a common factor in testicular dysfunction. J Androl 29:488\u2013498. https:\/\/doi.org\/10.2164\/jandrol.108.005132","journal-title":"J Androl"},{"key":"4525_CR128","doi-asserted-by":"publisher","unstructured":"Udaka K, Nakamura S, Fujii S, Miyamoto R, Matsui N, Kawata S, Hori T, Murai J, Sumitani R, Oura M, Sogabe K (2020) Successful treatment of progressive multifocal leukoencephalopathy with mirtazapine and mefloquine in refractory myeloma. Int\u00a0J Myeloma 10:8\u201312. https:\/\/doi.org\/10.57352\/ijm.10.1_8","DOI":"10.57352\/ijm.10.1_8"},{"key":"4525_CR129","doi-asserted-by":"publisher","first-page":"387","DOI":"10.9758\/cpn.23.1103","volume":"22","author":"K Ueno","year":"2023","unstructured":"Ueno K, Ishitobi M, Kosaka H, Ichijo K, Nagase Y (2023) Mirtazapine monotherapy for antipsychotics-refractory psychosis in a patient with very-late-onset schizophrenia-like psychosis: a case report. Clin Psychopharmacol Neurosci 22:387\u2013389. https:\/\/doi.org\/10.9758\/cpn.23.1103","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"4525_CR130","doi-asserted-by":"publisher","unstructured":"Usnich T, Hauptmann B, Hanssen H, Prasuhn J, Balck A, Borsche M, Tadic V, Klee A, Noblejas-Sanchez G, Vollstedt EJ, Klein C (2023) Depressive symptoms in Parkinson\u2019s disease are insufficiently but more often treated than in other chronic conditions. npj Parkinson\u2019s Dis 9:113\u00a0https:\/\/doi.org\/10.1038\/s41531-023-00551-8","DOI":"10.1038\/s41531-023-00551-8"},{"key":"4525_CR131","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.1038\/srep05433","volume":"4","author":"K Uzawa","year":"2014","unstructured":"Uzawa K, Kasamatsu A, Shimizu T, Saito Y, Baba T, Sakuma K, Fushimi K, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H (2014) Suppression of metastasis by mirtazapine via restoration of the Lin-7C\/\u03b2-catenin pathway in human cancer cells. Sci Rep 4:5433. https:\/\/doi.org\/10.1038\/srep05433","journal-title":"Sci Rep"},{"key":"4525_CR132","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ebcr.2016.06.002","volume":"6","author":"NM Warner","year":"2016","unstructured":"Warner NM, Gwinn RP, Doherty MJ (2016) Individualizing therapies with responsive epilepsy neurostimulation\u2014a mirtazapine case study of hippocampal excitability. Epilepsy Behav Case Rep 6:70\u201372. https:\/\/doi.org\/10.1016\/j.ebcr.2016.06.002","journal-title":"Epilepsy Behav Case Rep"},{"key":"4525_CR133","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.3724\/abbs.2022164","volume":"54","author":"S Wu","year":"2022","unstructured":"Wu S, Li X, Li P, Li T, Huang G, Sun Q, Dinny\u00e9s A, Shang L, Xu W (2022) Developing rat testicular organoid models for assessing the reproductive toxicity of antidepression drugs in vitro: Testicular organoids to assess antidepressants toxicity. Acta Biochim Biophys Sin 54:1748. https:\/\/doi.org\/10.3724\/abbs.2022164","journal-title":"Acta Biochim Biophys Sin"},{"key":"4525_CR134","first-page":"9511","volume":"11","author":"W Xing","year":"2018","unstructured":"Xing W, Hu M, Zhang G (2018) Mirtazapine in combination with serotonin re-uptake inhibitors improves depression and anxiety in patients with PTSD. Int J Clin Exp Med 11:9511\u20139519","journal-title":"Int J Clin Exp Med"},{"key":"4525_CR135","doi-asserted-by":"publisher","first-page":"100068","DOI":"10.1016\/j.pscia.2025.100068","volume":"3","author":"K Yamada","year":"2025","unstructured":"Yamada K, Kihara T, Shinsato K, Yasui H, Shino M, Sato H, Onoue S (2025) Nasal powder formulation employing microenvironmental pH-modifier for rapid absorption of mirtazapine. Pharm Sci Adv 3:100068. https:\/\/doi.org\/10.1016\/j.pscia.2025.100068","journal-title":"Pharm Sci Adv"},{"key":"4525_CR136","doi-asserted-by":"publisher","first-page":"764262","DOI":"10.1155\/2013\/764262","volume":"2013","author":"NA Yener","year":"2013","unstructured":"Yener NA, Sinanoglu O, Ilter E, Celik A, Sezgin G, Midi A, Deveci U, Aksungar F (2013) Effects of spirulina on cyclophosphamide-induced ovarian toxicity in rats: biochemical and histomorphometric evaluation of the ovary. Biochem Res Int 2013:764262. https:\/\/doi.org\/10.1155\/2013\/764262","journal-title":"Biochem Res Int"},{"key":"4525_CR137","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.3109\/03639045.2015.1104345","volume":"42","author":"S Y\u0131ld\u0131z","year":"2016","unstructured":"Y\u0131ld\u0131z S, Aytekin E, Yavuz B, Bozda\u011f Pehlivan S, \u00dcnl\u00fc N (2016) Formulation studies for mirtazapine orally disintegrating tablets. Drug Dev Ind Pharm 42:1008\u20131017. https:\/\/doi.org\/10.3109\/03639045.2015.1104345","journal-title":"Drug Dev Ind Pharm"},{"key":"4525_CR138","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1080\/10837450.2017.1315670","volume":"23","author":"S Y\u0131ld\u0131z","year":"2018","unstructured":"Y\u0131ld\u0131z S, Aytekin E, Yavuz B, Bozda\u011f Pehlivan S, Vural \u0130, \u00dcnl\u00fc N (2018) Development and evaluation of orally disintegrating tablets comprising taste-masked mirtazapine granules. Pharm Dev Technol 23:488\u2013495. https:\/\/doi.org\/10.1080\/10837450.2017.1315670","journal-title":"Pharm Dev Technol"},{"key":"4525_CR139","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.jagp.2019.03.021","volume":"27","author":"M Zuidersma","year":"2019","unstructured":"Zuidersma M, Chua KC, Hellier J, Voshaar RO, Banerjee S, HTA-SADD Investigator Group (2019) Sertraline and mirtazapine versus placebo in subgroups of depression in dementia: findings from the HTA-SADD randomized controlled trial. Am J Geriatr Psychiatry 27:920\u2013931. https:\/\/doi.org\/10.1016\/j.jagp.2019.03.021","journal-title":"Am J Geriatr Psychiatry"},{"key":"4525_CR140","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clinbiochem.2019.04.015","volume":"72","author":"M Zv\u011b\u0159ov\u00e1","year":"2019","unstructured":"Zv\u011b\u0159ov\u00e1 M (2019) Clinical aspects of Alzheimer\u2019s disease. Clin Biochem 72:3\u20136. https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.04.015","journal-title":"Clin Biochem"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04525-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04525-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04525-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T01:09:54Z","timestamp":1771549794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04525-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":140,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4525"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04525-w","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}